Motus GI Bolsters Commercial and Quality/Regulatory Expertise with Two Key Senior Management Additions

– Purposefully built Management Team to drive commercial launch of
Pure-Vu® GEN2 in the U.S. hospital market –

– Recent FDA approval and strong clinical results from REDUCE study
position Pure-Vu® GEN2 as potential new standard of care in a market
segment with approximately 1.5 million critical colonoscopy inpatient
procedures performed annually in the U.S.

GI Holdings, Inc.
, (NASDAQ: MOTS) (“Motus GI” or the “Company”), a
medical technology company dedicated to improving clinical outcomes and
enhancing the cost-efficiency of colonoscopy, announced today the
appointments of Steven M. Bosrock as Vice President of Global Marketing
& Strategy and George G. Peters as Vice President of Quality &
Regulatory Affairs.

“As we work towards the commercial launch of the Pure-Vu® GEN2,
purposefully building a Management Team with diverse skillsets and
proven expertise has been a key priority for the Company. The strategic
appointments of Steve and George bring extensive experience in
navigating regulatory pathways and launching novel products in
significant markets. We continue to be on target for our commercial
launch of Pure-Vu® GEN2, having just received clearance from the FDA,”
commented Tim
Moran, Chief Executive Officer of Motus GI.

Motus GI recently announced its receipt of Special 510(k) clearance from
the FDA for the second-generation Pure-Vu® System (“Pure-Vu® GEN2”) to
help facilitate the cleaning of a poorly prepared colon during the
colonoscopy procedure. Pure-Vu® GEN2 has been designed to improve the
mobility, setup logistics of the system and enhance navigation through
the colon, while retaining all the same cleansing functionality as the
first generation of the Pure-Vu® System.

Steven M. Bosrock joins as Vice President of Global Marketing &

Mr. Bosrock brings to Motus GI significant experience introducing novel
products in multiple market opportunities. His proven track record of
building brands, teams, and commercial organizations leading to
sustainable growth are key traits he brings to the Motus GI team to
drive Pure-Vu® into the market. Most recently he served as Vice
President of Marketing at Torax Medical Incorporated, a privately held
medical device company acquired by Johnson and Johnson (NYSE: JNJ), that
developed and marketed the FDA approved LINX system to treat
gastro-esophageal reflux disease (GERD). Mr. Bosrock was responsible for
Torax Medical’s U.S. marketing strategy for the launch of LINX. Prior to
Torax Medical, Mr. Bosrock served as Director of Marketing at Synovis
Life Technologies, a publicly traded advanced biosurgical device company
that was acquired by Baxter International Inc. Additionally, Mr. Bosrock
held corporate business development and marketing roles at Eli Lilly and
Company including responsibility for development and implementation of
the U.S. launch of Forteo®, a novel treatment for severe osteoporosis.

“I am excited to join the talented team at Motus GI at such a pivotal
time in the Company’s evolution. I believe the Pure-Vu® System is an
innovative solution that addresses a significant area of unmet need in
the colonoscopy market. Over the course of my career, I have built
several brands and led the launch of multiple products and I look
forward to leveraging my market development experience as we prepare to
launch and drive adoption of this important technology,” stated Mr.

George G. Peters joins as Vice President of Quality & Regulatory

Mr. Peters brings to Motus GI over 25 years of engineering,
manufacturing, quality and regulatory experience. Mr. Peters’ proven
ability to work with regulatory agencies and drive a culture of quality
has been a hallmark of his career. Most recently he served as Vice
President of Quality Systems at Flowonix Medical, Inc., a class III PMA
electro-mechanical medical device start-up company. Prior to that, Mr.
Peters served as Sr. Director, Quality & Logistics at Metacure (USA), a
class III PMA electro-mechanical medical device start-up company, as
well as a variety of roles in quality assurance and regulatory
compliance at Datascope Corp., Interventional Products Division and
Cardiac Assist Division.

Mr. Peters commented, “As Motus GI continues to lay the foundation for
our technology in the hospital market, execution is going to be
critical. I look forward to being part of this highly experienced team
and applying my experience in regulatory and quality assurance to help
position the Pure-Vu® System as a potential new standard of care in

About Motus GI and the Pure-Vu® System

Motus GI Holdings, Inc. is a medical technology company, with
subsidiaries in the U.S. and Israel, dedicated to improving clinical
outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s
flagship product is the Pure-Vu® System, a U.S. FDA cleared medical
device indicated to help facilitate the cleaning of a poorly prepared
colon during the colonoscopy procedure. The device integrates with
standard and slim colonoscopes to enable safe and rapid cleansing during
the procedure while preserving established procedural workflow and
techniques. The first generation of the Pure-Vu® System has received CE
mark approval in Europe. The Pure-Vu® System is currently being
introduced on a pilot basis in the U.S. market, and the Company is
planning to initiate a commercial launch focused on the U.S. hospital
market in 2019. Challenges with bowel preparation for inpatient
colonoscopy represent a significant area of unmet need that directly
affects clinical outcomes and increases the cost of care in a market
segment that comprises approximately 1.5 million annual procedures in
the U.S. and approximately 4 million annual procedures worldwide. Motus
GI believes the Pure-Vu® System may improve outcomes and lower costs for
hospitals by reducing the time to successful colonoscopy, minimizing
delayed and incomplete procedures, and improving the quality of an exam.
In clinical studies to date, the Pure-Vu® System significantly increased
the number of patients with an adequate cleansing level, according to
the Boston Bowel Preparation Scale Score, a validated assessment

For more information, visit
and connect with the Company on Twitter,
and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements.
Forward-looking statements are based on the Company’s current
expectations and assumptions. The Private Securities Litigation Reform
Act of 1995 provides a safe-harbor for forward-looking statements. These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,” “intend,” “plan,”
“believe,” “estimate,” “potential,” “predict,” “project,” “should,”
“would” and similar expressions and the negatives of those terms,
including without limitation, risks inherent in the development and
commercialization of potential products, uncertainty in the timing and
results of clinical trials or regulatory approvals, maintenance of
intellectual property rights or other risks discussed in the Company’s
Form 10-K filed on March 26, 2019, and its other filings with the
Securities and Exchange Commission. Prospective investors are cautioned
not to place undue reliance on such forward-looking statements, which
speak only as of the date hereof. The Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise.


Jenene Thomas
Thomas Communications, LLC
(833) 475-8247

A. Sandoval
Lazar Partners
(917) 497-2867

error: Content is protected !!